GBM AGILE Overview – new

GBM AGILE

GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed and recurrent GBM.
clinicaltrials.gov ID: NCT03970447

THE CHALLENGE

There is currently no known cure for glioblastoma.

48 %

GBM accounts for 48% of all primary malignant brain cancers

15

Median Survival for Patients with GBM is just under 15 months

3

Only 3 drugs for GBM have been approved over the last 40 years

EXPLORE GBM AGILE

Whether you're considering GBM AGILE as a clinical trial or looking to learn more about partnering, find the information that's most relevant to you.

For Patients

Learn more about GBM AGILE, including participating trial locations and answers to frequently asked questions.

For Pharma, Biotech & Research Collaborators

Discover more about GBM AGILE and the collaborative effort behind it, including the trial design, leadership, and participating organizations.

EXPLORE OTHER GCAR TRIALS

GBM AGILE is part of GCAR’s growing portfolio of adaptive clinical trials. Explore other trials in development and the work underway to advance research across additional diseases.